Bob Lutz is Principal Consultant at Crescendo Biopharma Consulting and has extensive experience in the development of antibody-based therapeutics. He has been providing C-level support to emerging biotech and pharma since 2015. Prior to initiating his consulting practice, Bob held various R&D roles over 23 years at ImmunoGen, Inc, where he was Vice President of Translational Research and Development, with responsibility for all early stage antibody–drug conjugate (ADC) development programs. He was also a member of ImmunoGen’s portfolio research committee, served on numerous alliance committees supporting the R&D programs of ImmunoGen’s licensed partners, and was ImmunoGen’s research lead on Genentech’s trastuzumab emtansine (T-DM1) program.
Bob earned his PhD in Biochemistry at Brandeis University and was a research and postdoctoral fellow at the Eleanor Roosevelt Institute in Colorado, USA.
Press return to search